• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr. Adil Daud Discusses Zelboraf and Yervoy for the Treatment of Metastatic Melanoma

Article

Dr. Adil Daud, Clinical Professor of Medicine and Co-Director of the Melanoma Program, UCSF, discusses cost and the payer/provider relationship around metastatic melanoma medications.

vemurafenib (Brand name:

Dr. Daud discusses the use of Zelboraf) and ipilimumab (Brand name: Yervoy), the FDA-approved medications used in the treatment of metastatic melanoma. The medications are expensive, but Dr. Daud shares there have been little issue covering these specific drugs since they are so effective. Dr. Daud hopes that these are only the first class of this drug pathway extending life expectancy, as he hopes they can eventually bring metastatic melanoma to a chronic disease state and not a death sentence.

Related Videos
Elena Elimova, MD, associate professor in the Department of Medicine at the University of Toronto and staff medical oncologist at Princess Margaret Hospital
Dr Eric Yang
Adam Brufsky, MD, PhD, University of Pittsburgh
Enrique Velazquez Villarreal, MD, PhD, MPH, MS, assistant professor in the department of integrative translational sciences at City of Hope
Dr Marco Del Riccio
Dr Steven Manobianco
Dr David Kuter
Roy Mathew, MD, screenshot
Dr Marco del Riccio
© 2026 MJH Life Sciences
AJMC®
All rights reserved.